MSD's efforts to combine cancer immunotherapy Keytruda with its AstraZeneca-partnered PARP drug Lynparza have so far failed – but at last it can point to a partial win in a phase 3 trial. The new data ...
A year ago, MSD and Daiichi Sankyo's HER3-targeting antibody-drug conjugate patritumab deruxtecan (HER3-DXd) was rejected by the FDA, and the partners have now withdrawn a filing intended to get the ...
Machine learning is the ability of a machine to improve its performance based on previous results. Machine learning methods enable computers to learn without being explicitly programmed and have ...
Send your kids to these sites to help them learn, study, indulge their curiosity, and get a fresh perspective on academic subjects. I'm an expert in software and work-related issues, and I have been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback